Table 1 Basic demographic and clinical data distribution of the studied patients
From: Evaluation of the efficacy of pirfenidone in progressive chronic hypersensitivity pneumonitis
Group 1 | Group 2 | t/X2 | P | |||
|---|---|---|---|---|---|---|
Age(year) | 48.65 ± 8.59 | 44.55 ± 7.46 | 1.611 | 0.115 | ||
BMI (kg/m2) | 28.98 ± 4.85 | 29.13 ± 3.99 | 0.784 | 0.485 | ||
Duration (year) | 1.85 ± 0.62 | 1.77 ± 0.57 | − 0.851 | 0.412 | ||
Sex | Female | N | 6 | 7 | ||
% | 30.0 | 35.0 | ||||
Male | N | 14 | 13 | 0.114 | 0.73 | |
% | 70.0 | 65.0 | ||||
Comorbid | No | N | 15 | 17 | ||
% | 75.0 | 85.0 | ||||
DM | N | 2 | 2 | 1.12 | 0.57 | |
% | 10.0 | 10.0 | ||||
HTN | N | 3 | 1 | |||
% | 15.0 | 5.0 | ||||
Total | N | 20 | 20 | |||
% | 100.0% | 100.0 | ||||